StreetInsider.com News Articles

Enhertu® Wins 2026 International Prix Galien Award for Best Biotechnology Product

Fri, 30 Oct 2026 07:00:00 -0500

Second Prix Galien Award for Daiichi Sankyo and AstraZeneca’s Enhertu following receipt of the Prix Galien USA Award in 2024

TOKYO--(BUSINESS WIRE)-- Enhertu® (trastuzumab deruxtecan) has been awarded the 2026 International Prix Galien Award for Best Biotechnology Product, a recognition awarded every two years by The Galien Foundation. This is the second award granted to Enhertu, following receipt of the Prix Galien USA Award for Best Biotechnology Product in 2024.

The Prix Galien is among the global health innovation industry’s most renowned honors, recognizing outstanding biomedical and medical technology product achievements that improve the human condition, and is

Enhertu® Wins 2026 International Prix Galien Award for Best Biotechnology Product

Fri, 30 Oct 2026 07:00:00 -0500

Second Prix Galien Award for Daiichi Sankyo and AstraZeneca’s Enhertu following receipt of the Prix Galien USA Award in 2024

Enhertu® Wins 2026 International Prix Galien Award for Best Biotechnology Product

Fri, 30 Oct 2026 07:00:00 -0500

Second Prix Galien Award for Daiichi Sankyo and AstraZeneca’s Enhertu following receipt of the Prix Galien USA Award in 2024

Enhertu® Wins 2026 International Prix Galien Award for Best Biotechnology Product

Fri, 30 Oct 2026 07:00:00 -0500

Second Prix Galien Award for Daiichi Sankyo and AstraZeneca’s Enhertu following receipt of the Prix Galien USA Award in 2024

Daiichi Sankyo Reports Second Quarter Fiscal Year 2026 Financial Results

Fri, 30 Oct 2026 00:15:00 -0500

Revenue increased 19.7% to 1.167 trillion yen year-over-year driven by Enhertu® and Datroway®
Fiscal year 2026 guidance for revenue and operating profit remains unchanged
Earnings call to take place on Friday, October 30 at 5:30 pm Japan Standard Time

TOKYO--(BUSINESS WIRE)-- Daiichi Sankyo (TSE: 4568) reported financial results for the second quarter of fiscal year 2026, ending September 30, 2026.

“Strong revenue growth continues in the second quarter of fiscal year 2026, driven by Enhertu and Datroway. These medicines have received nine new approvals across multiple indications since last quarter, including same day breast cancer approvals in Japan and China,

Daiichi Sankyo Reports Second Quarter Fiscal Year 2026 Financial Results

Fri, 30 Oct 2026 00:15:00 -0500

Revenue increased 19.7% to 1.167 trillion yen year-over-year driven by Enhertu® and Datroway®
Fiscal year 2026 guidance for revenue and operating profit remains unchanged
Earnings call to take place on Friday, October 30 at 5:30 pm Japan Standard Time

TOKYO--(BUSINESS WIRE)-- Daiichi Sankyo (TSE: 4568) reported financial results for the second quarter of fiscal year 2026, ending September 30, 2026.

Two Single-Pill Triple Combination Lipid-Lowering Therapy Applications Validated in The European Union

Thu, 29 Oct 2026 07:27:00 -0500

EMA has validated two marketing authorization applications from Daiichi Sankyo in the EU for single-pill triple-combinations of established lipid-lowering agents: bempedoic acid, ezetimibe, and either atorvastatin or rosuvastatin
If approved, the proposed therapies could be the first oral single-pill triple-combinations for lipid-lowering in the EU, aiming to simplify treatment for patients requiring multiple lipid-lowering agents
The submissions reflect the commitment of Daiichi Sankyo to addressing unmet needs in cardiovascular disease

MUNICH--(BUSINESS WIRE)-- The European Medicines Agency (EMA) has validated two marketing authorization applications (MAA) from Daiichi Sankyo (TSE: 4568) for oral, single-pill triple-combination therapies. The applications seek approval for

Two Single-Pill Triple Combination Lipid-Lowering Therapy Applications Validated in The European Union

Thu, 29 Oct 2026 07:27:00 -0500

EMA has validated two marketing authorization applications from Daiichi Sankyo in the EU for single-pill triple-combinations of established lipid-lowering agents: bempedoic acid, ezetimibe, and either atorvastatin or rosuvastatin
If approved, the proposed therapies could be the first oral single-pill triple-combinations for lipid-lowering in the EU, aiming to simplify treatment for patients requiring multiple lipid-lowering agents
The submissions reflect the commitment of Daiichi Sankyo to addressing unmet needs in cardiovascular disease

Enhertu Approved in the EU as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer

Tue, 27 Oct 2026 04:20:40 -0500

Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization [ISH]+) breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment.

Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN).

The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of

Enhertu Approved in the EU as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer

Tue, 27 Oct 2026 04:20:40 -0500

The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of

Enhertu® Approved in the EU as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer

Tue, 27 Oct 2026 03:30:00 -0500

Approval based on DESTINY-Breast05 phase 3 trial results that showed Daiichi Sankyo and AstraZeneca’s Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1
First EU approval of Enhertu in the curative-intent early breast cancer setting
Third approval for Enhertu in the EU in four months

TOKYO--(BUSINESS WIRE)-- Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization [ISH]+) breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment.

Enhertu is

Enhertu® Approved in the EU as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer

Tue, 27 Oct 2026 03:30:00 -0500

Approval based on DESTINY-Breast05 phase 3 trial results that showed Daiichi Sankyo and AstraZeneca’s Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1
First EU approval of Enhertu in the curative-intent early breast cancer setting
Third approval for Enhertu in the EU in four months

Enhertu is

Enhertu® Approved in the EU as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer

Tue, 27 Oct 2026 03:30:00 -0500

Approval based on DESTINY-Breast05 phase 3 trial results that showed Daiichi Sankyo and AstraZeneca’s Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1
First EU approval of Enhertu in the curative-intent early breast cancer setting
Third approval for Enhertu in the EU in four months

Enhertu is

Enhertu® Approved in the EU as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer

Tue, 27 Oct 2026 03:30:00 -0500

Approval based on DESTINY-Breast05 phase 3 trial results that showed Daiichi Sankyo and AstraZeneca’s Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1
First EU approval of Enhertu in the curative-intent early breast cancer setting
Third approval for Enhertu in the EU in four months

Enhertu is

Daiichi Sankyo Highlights Ongoing Progress Across Industry-Leading ADC Portfolio with New Research Updates at ESMO

Thu, 22 Oct 2026 07:00:00 -0500

New data from six landmark trials reinforce practice-changing results of Enhertu and Datroway across a broad spectrum of patients in breast and lung cancer
Additional analyses from two trials of raludotatug deruxtecan in ovarian cancer demonstrate emerging potential in gynecological cancers

TOKYO--(BUSINESS WIRE)-- Daiichi Sankyo (TSE: 4568) will present new clinical research across its oncology portfolio with more than 30 abstracts, including four late breaking presentations, in multiple cancers at the 2026 European Society for Medical Oncology (#ESMO26) Congress.

New data from six landmark trials demonstrate the company’s progress toward advancing new standards of care for patients in breast

Daiichi Sankyo Highlights Ongoing Progress Across Industry-Leading ADC Portfolio with New Research Updates at ESMO

Thu, 22 Oct 2026 07:00:00 -0500

New data from six landmark trials reinforce practice-changing results of Enhertu and Datroway across a broad spectrum of patients in breast and lung cancer
Additional analyses from two trials of raludotatug deruxtecan in ovarian cancer demonstrate emerging potential in gynecological cancers

New data from six landmark trials demonstrate the company’s progress toward advancing new standards of care for patients in breast

Daiichi Sankyo Company, Limited (4568:JP) (DSNKY) PT Lowered to JPY3,800 at Nomura/Instinet

Tue, 13 Oct 2026 06:23:48 -0500

Nomura/Instinet analyst Hiroyuki Matsubara lowered the price target on Daiichi Sankyo Company, Limited (4568:JP) (OTC: DSNKY) to JPY3,800.00 (from JPY4,000.00) while maintaining a Buy rating.

Daiichi Sankyo Company, Limited (4568:JP) (DSNKY) PT Lowered to JPY3,800 at Nomura/Instinet

Tue, 13 Oct 2026 06:23:48 -0500

Nomura/Instinet analyst Hiroyuki Matsubara lowered the price target on Daiichi Sankyo Company, Limited (4568:JP) (OTC: DSNKY) to JPY3,800.00 (from JPY4,000.00) while maintaining a Buy rating.

Daiichi Sankyo Company, Limited (4568:JP) (DSNKY) PT Lowered to JPY3,800 at Nomura/Instinet

Tue, 13 Oct 2026 06:23:48 -0500

Nomura/Instinet analyst Hiroyuki Matsubara lowered the price target on Daiichi Sankyo Company, Limited (4568:JP) (OTC: DSNKY) to JPY3,800.00 (from JPY4,000.00) while maintaining a Buy rating.

Daiichi Sankyo Company, Limited (4568:JP) (DSNKY) PT Lowered to JPY3,800 at Nomura/Instinet

Tue, 13 Oct 2026 06:23:48 -0500

Nomura/Instinet analyst Hiroyuki Matsubara lowered the price target on Daiichi Sankyo Company, Limited (4568:JP) (OTC: DSNKY) to JPY3,800.00 (from JPY4,000.00) while maintaining a Buy rating.

Daiichi Sankyo Company, Limited (4568:JP) (DSNKY) PT Lowered to JPY4,700 at Citi

Wed, 07 Oct 2026 08:21:12 -0500

Citi analyst Hidemaru Yamaguchi lowered the price target on Daiichi Sankyo Company, Limited (4568:JP) (OTC: DSNKY) to JPY4,700.00 (from JPY4,900.00) while maintaining a Buy rating.

Daiichi Sankyo Company, Limited (4568:JP) (DSNKY) PT Lowered to JPY4,700 at Citi

Wed, 07 Oct 2026 08:21:12 -0500

Citi analyst Hidemaru Yamaguchi lowered the price target on Daiichi Sankyo Company, Limited (4568:JP) (OTC: DSNKY) to JPY4,700.00 (from JPY4,900.00) while maintaining a Buy rating.

Daiichi Sankyo Company, Limited (4568:JP) (DSNKY) PT Lowered to JPY4,700 at Citi

Wed, 07 Oct 2026 08:21:12 -0500

Citi analyst Hidemaru Yamaguchi lowered the price target on Daiichi Sankyo Company, Limited (4568:JP) (OTC: DSNKY) to JPY4,700.00 (from JPY4,900.00) while maintaining a Buy rating.

Daiichi Sankyo Company, Limited (4568:JP) (DSNKY) PT Lowered to JPY4,700 at Citi

Wed, 07 Oct 2026 08:21:12 -0500

Citi analyst Hidemaru Yamaguchi lowered the price target on Daiichi Sankyo Company, Limited (4568:JP) (OTC: DSNKY) to JPY4,700.00 (from JPY4,900.00) while maintaining a Buy rating.

Daiichi Sankyo and AstraZeneca Enter into Clinical Trial Collaboration with Summit Therapeutics to Evaluate Datroway® in Combination with Ivonescimab Across Multiple Tumor Types

Fri, 02 Oct 2026 02:30:00 -0500

TOKYO--(BUSINESS WIRE)-- Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/NYSE: AZN) have entered into a clinical trial collaboration agreement with Summit Therapeutics Inc. (Nasdaq: SMMT) to evaluate Datroway® (datopotamab deruxtecan) in combination with ivonescimab across multiple tumor types including lung and breast cancers. The companies intend to begin with a phase 3 trial in first-line triple negative breast cancer (TNBC).

Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca.

“At Daiichi Sankyo, we are focused on maximizing the potential of our DXd